Quality Assessment and Clinical Utility of Plasma Obtained Via Apheresis vs That Obtained from Whole Blood.

Published in: Laboratory medicine (2022)

AP demonstrated considerably greater factor activity. This would be beneficial when manufacturing clotting factor concentrates. Large scale clinical trials are needed to further address the hemostatic outcomes of both products in massively transfused patients.

Keyphrases

clinical trial
end stage renal disease
chronic kidney disease
ejection fraction
newly diagnosed
peritoneal dialysis
transcription factor
prognostic factors
type diabetes
metabolic syndrome
adipose tissue
patient reported outcomes
insulin resistance
patient reported
phase ii
phase iii